Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma
- PMID: 27392425
- DOI: 10.1016/j.jhep.2016.06.023
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma
Comment in
-
Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".J Hepatol. 2017 Dec;67(6):1357. doi: 10.1016/j.jhep.2017.08.001. Epub 2017 Aug 9. J Hepatol. 2017. PMID: 28800877 No abstract available.
-
Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.J Hepatol. 2017 Dec;67(6):1355-1356. doi: 10.1016/j.jhep.2017.07.026. Epub 2017 Aug 10. J Hepatol. 2017. PMID: 28803950 No abstract available.
Comment on
-
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13. J Hepatol. 2016. PMID: 27084592
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
